

REMARKS

Claims 1 to 7, and 16-18 are pending. Claim 1 has been amended to cancel non-elected subject matter. Claim 17 is new. Support for claim 17 can be found in the specification at page 6, line 17, *et seq.* Support for new claim 18 can be found in the examples. No new matter is added.

35 U.S.C. § 112, first paragraph

Claims 1-7 and 16 stand rejected under § 112, first paragraph for the inclusion of the term "prodrug." This term has been deleted from the claims.

35 U.S.C. § 112, second paragraph


Claims 1-7 and 16 stand rejected as indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 1, 3, 4 and 7 have been amended in accordance with the examiner's suggestions. Accordingly, withdrawal of the rejection is respectfully requested.

35 U.S.C. § 102 (b)

Claims 1-2 stand rejected under 35 U.S.C. § 102 (b) as allegedly anticipated by U.S. Pat. 4,389,416. However, the compounds disclosed in the cited reference are not within the scope of the amended claims. Reconsideration and withdrawal of the rejection is therefore, respectfully requested.

Applicants believe that the claims are now in condition for allowance. An early Office Action to that effect is therefore, earnestly solicited.

Respectfully submitted,



Maureen S. Gibbons
Attorney for Applicant
Reg. No. 44,121
Phone: 609-252-3453
Date: June 25, 2007

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000